SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverTEM
TechnologyNasdaqGSUSD

Tempus AI, Inc.

$0012345678900123456789.0012345678900123456789+6.0%
52w low (est.) $42.34$68.06 52w high (est.)
Market data
52-week range
USD41.73 – USD104.32
Beta (vs market)
1.00
Sector
Technology

About Tempus AI, Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Valuation

Overall Rating
0
Not rated
Not rated
Moat Score0
DCF Intrinsic Value
Not covered by our valuation model yet.

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD0.00
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
0.0%
Profit Margin
0.0%
ROE
0.0%
Debt / Equity
0.00
Beta
1.00
vs Technology sector:Moat 0 vs 10Yield 0.00% vs 0.1%

Statistics

Similar Stocks · Technology

MSFT78
$441.20+0.8%
AAPL74
$228.50+1.2%
AVGO74
$1,700.00+1.4%
NVDA71
$124.30+3.4%

Latest News · TEM